MFMasayuki Fukata

Masayuki Fukata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Masayuki Fukata has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sa1822 TRIF Regulates IL-17 Expressing Cell Expansion During Enteric Infection With Gram-Negative Bacteria

    by Saravana Kanagavelu, James M. Termini, Kristina Chung, Jose R. Ruiz, Laura Romero, Masayuki Fukata

  • Sa1766 Tir-Domain-Containing Adapter-Inducing Interferon-β (TRIF) Regulates TH17-Mediated Immunopathology During Intestinal Inflammation

    by Saravana Kanagavelu, James M. Termini, Kristina Chung, Jose R. Ruiz, Laura Romero, Masayuki Fukata

  • Open Access

    TLR4 Activates the B-Catenin Pathway to Cause Intestinal Neoplasia

    by Rebeca Santaolalla, Jose Ruiz, Julie Davies, Daniel Sussman, Cristhine Pastorini, Cecilia Espana, Oname Burlingame, Pablo Bejarano, Negar Rassaei, Jeffrey Ko, et al.

    Colonic bacteria have been implicated in the development of colon cancer. We have previously demonstrated that toll-like receptor 4 (TLR4), the receptor for bacterial lipopolysaccharide, is over-expressed in humans with ulcerative colitis-associated cancer. We aimed to determine whether TLR4 plays a role as a tumor promoter in the absence of inflammation. In vivo studies were performed using villin-TLR4 mice, which we generated to over-express TLR4 in the intestinal epithelium, and C57BL/6J wild type mice as controls. Colonic tumorigenesis was induced using the genotoxic agent azoxymethane (AOM). Cell proliferation was assessed by BrdU labeling, and β-catenin was stained by immunohistochemistry. Colon specimens at baseline and after AOM were scored for histological inflammation by three pathologists blinded to the mouse strain and treatment. In vitro experiments were performed using SW480 and IEC-6 intestinal epithelial cell lines. We found that at baseline villin-TLR4 mice had increased epithelial proliferation as well as longer crypts, compared to wild type mice. In addition, villin-TLR4 mice developed spontaneous duodenal adenomas. In wild-type mice, AOM treatment rarely resulted in tumors. By contrast, AOM induced robust colonic tumorigenesis in villin-TLR4 mice. Furthermore, villin-TLR4 mice were more likely to develop larger quantities of tumors than wild-type mice. Histologically, these tumors ranged from low-grade to high-grade dysplasia and carcinoma in situ similar to adenomatous polyps in humans. Moreover, histological scoring of villin-TLR4 and wild-type mice before and after AOM did not reveal any acute inflammation. Tumors arising in villin-TLR4 mice are characterized by intense nuclear β-catenin staining. In addition, villin-TLR4 mice showed an increase in β-catenin nuclear translocation as well as a greater cell proliferation in non-dysplastic colon compared to wild-type mice. Biochemical studies in colonic epithelial cells lines revealed that TLR4 activates β-catenin in a PI3K-dependent manner. Over-expression of TLR4 increases the risk of colon neoplasia even in the absence of inflammation. Our studies highlight a previously unexplored link between innate immune signaling and activation of oncogenic pathways, which may be targeted to prevent or treat colorectal cancer.


  • Open Access

    Transcriptional Regulation of IL-10 Expression by Peroxisome Proliferator-Activated Receptor (Pparγ) in Human Intestinal Epithelial Cells

    by Jinhee Hyun, Saravana Kanagavelu, Jose Ruiz, Masayuki Fukata

    IL-10 is an important immunomodulatory cytokine in the regulation of intestinal inflammation in inflammatory bowel disease (IBD). PPARγ is a nuclear receptor known to modulate transcriptional activities of many cytokines and is highly expressed in intestinal epithelial cells (IECs). Human IECs have been shown to express IL-10, but how its expression is regulated remains obscure especially in the setting of inflammation. We have demonstrated that intestinal 15d-PGJ2 (an endogenous PPARγ ligand) is predominantly induced by infiltrated macrophages (Mφs) through toll-like receptor 4 (TLR4)-mediated Cox-2 induction during colitis. In this study, we addressed whether PPARγ activation regulates expression of IL-10 in IECs. Human IEC cell line SW480-APC expressing TLR4 (top) and mouse peritoneal Mφs (bottom) were co-cultured in transwells. 15d-PGJ2 production and IL-10 mRNA expression were measured by enzyme linked assay and real-time PCR in the presence or absence of lipopolysaccharide (LPS). In order to examine whether the IL-10 promoter has PPARγ responsive elements, a 2,000 bp of IL-10 promoter was cloned from SW480-APC genomic DNA into the luciferase reporter vector. Expression and activity of PPARγ were blocked by siRNA and a specific inhibitor SR202, respectively. The IL-10 promoter activity was analyzed by luciferase reporter assay. PPARγ activity was confirmed using a reporter vector PPRE X3-TK-luc. Co-culturing SW480-APC with Mφs increased IL-10 expression in IECs within 24 hours, which was significantly enhanced by LPS stimulation in later time point (72 hours). LPS stimulation of SW480-APC resulted in PPARγ activation peaked at 48 hours. During SW480-APC/Mφ co-culture, LPS stimulation induced 15d-PGJ2 production, which is abolished when TLR4-deficient Mφs were used. Knocking down the expression of PPARγ suppressed IL-10 promoter activity and mRNA expression in SW480-APC in baseline as well as after LPS stimulation. These results suggest that PPARγ positively regulates IL-10 expression in IECs at the transcriptional level. During inflammation, mucosal Mφs induce PPARγ ligand (15d-PGJ2) in a TLR4-dependent manner that contributes to PPARγ activation in IECs and thus IL-10 expression. This may be an intrinsic immunoregulatory program that is mediated through host-bacterial interactions, which dampens on-going inflammation during intestinal inflammation and thus can be a novel therapeutic target for IBD.

  • Open Access

    TLR4 Activates the B-Catenin Pathway to Cause Intestinal Neoplasia

    by Rebeca Santaolalla, Jose Ruiz, Julie Davies, Daniel Sussman, Cristhine Pastorini, Cecilia Espana, Oname Burlingame, Pablo Bejarano, Negar Rassaei, Jeffrey Ko, et al.

    Colonic bacteria have been implicated in the development of colon cancer. We have previously demonstrated that toll-like receptor 4 (TLR4), the receptor for bacterial lipopolysaccharide, is over-expressed in humans with ulcerative colitis-associated cancer. We aimed to determine whether TLR4 plays a role as a tumor promoter in the absence of inflammation. In vivo studies were performed using villin-TLR4 mice, which we generated to over-express TLR4 in the intestinal epithelium, and C57BL/6J wild type mice as controls. Colonic tumorigenesis was induced using the genotoxic agent azoxymethane (AOM). Cell proliferation was assessed by BrdU labeling, and β-catenin was stained by immunohistochemistry. Colon specimens at baseline and after AOM were scored for histological inflammation by three pathologists blinded to the mouse strain and treatment. In vitro experiments were performed using SW480 and IEC-6 intestinal epithelial cell lines. We found that at baseline villin-TLR4 mice had increased epithelial proliferation as well as longer crypts, compared to wild type mice. In addition, villin-TLR4 mice developed spontaneous duodenal adenomas. In wild-type mice, AOM treatment rarely resulted in tumors. By contrast, AOM induced robust colonic tumorigenesis in villin-TLR4 mice. Furthermore, villin-TLR4 mice were more likely to develop larger quantities of tumors than wild-type mice. Histologically, these tumors ranged from low-grade to high-grade dysplasia and carcinoma in situ similar to adenomatous polyps in humans. Moreover, histological scoring of villin-TLR4 and wild-type mice before and after AOM did not reveal any acute inflammation. Tumors arising in villin-TLR4 mice are characterized by intense nuclear β-catenin staining. In addition, villin-TLR4 mice showed an increase in β-catenin nuclear translocation as well as a greater cell proliferation in non-dysplastic colon compared to wild-type mice. Biochemical studies in colonic epithelial cells lines revealed that TLR4 activates β-catenin in a PI3K-dependent manner. Over-expression of TLR4 increases the risk of colon neoplasia even in the absence of inflammation. Our studies highlight a previously unexplored link between innate immune signaling and activation of oncogenic pathways, which may be targeted to prevent or treat colorectal cancer.


  • 175 TLR4 Activates LGR5 Expression in the Colon: A Link Between Cancer Stem Cells and Innate Immune Signals

    by Rebeca Santaolalla, Julie M. Davies, Jose Ruiz, Cecilia Espana, Masayuki Fukata, Maria T. Abreu

  • Open Access

    Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity

    by John Sotolongo, Cecilia España, Andrea Echeverry, David Siefker, Norman Altman, Julia Zaias, Rebeca Santaolalla, Jose Ruiz, Kurt Schesser, Becky Adkins, et al.

    Toll-like receptor 4 (TLR4), which signals through the adapter molecules myeloid differentiation factor 88 (MyD88) and toll/interleukin 1 receptor domain-containing adapter inducing IFN-β (TRIF), is required for protection against Gram-negative bacteria. TRIF is known to be important in TLR3-mediated antiviral signaling, but the role of TRIF signaling against Gram-negative enteropathogens is currently unknown. We show that TRIF signaling is indispensable for establishing innate protective immunity against Gram-negative Yersinia enterocolitica. Infection of wild-type mice rapidly induced both IFN-β and IFN-γ in the mesenteric lymph nodes. In contrast, TRIF-deficient mice were defective in these IFN responses and showed impaired phagocytosis in regional macrophages, resulting in greater bacterial dissemination and mortality. TRIF signaling may be universally important for protection against Gram-negative pathogens, as TRIF-deficient macrophages were also impaired in killing both Salmonella and Escherichia coli in vitro. The mechanism of TRIF-mediated protective immunity appears to be orchestrated by macrophage-induced IFN-β and NK cell production of IFN-γ. Sequential induction of IFN-β and IFN-γ leads to amplification of macrophage bactericidal activity sufficient to eliminate the invading pathogens at the intestinal interface. Our results demonstrate a previously unknown role of TRIF in host resistance to Gram-negative enteropathogens, which may lead to effective strategies for combating enteric infections.